{"entity":{"id":"nct05022901","kind":"trial","name":"An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma","aka":[],"tldr":"A phase 3 trial of Melphalan in melanoma and uveal melanoma, run by Delcath Systems Inc., active and no longer recruiting.","summary":"An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma is a phase 3 interventional study registered as NCT05022901 by Delcath Systems Inc., with 30 participants planned, started 2022-06-10 and due to reach its primary completion in 2024-03-01. Interventions recorded: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS). Conditions listed: Metastatic Ocular Melanoma, Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05022901","url":"https://clinicaltrials.gov/study/NCT05022901"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","uveal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["melphalan"],"companies":["delcath"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05022901","phase":"3","setting":"An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma","sponsor":"Delcath Systems Inc.","enrolled":30,"outcomes":[]},"route":"/trials/nct05022901/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"drug":[{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/"}],"company":[{"id":"delcath","kind":"company","name":"Delcath Systems","route":"/companies/delcath/"}]}}